Scientists at University of California San Diego School of Medicine used a machine learning algorithm to predict when cancer will resist chemotherapy.
Can AI-enabled technology safeguard hospitals, pharmacies, and medical devices from cyberattacks?
AI harnesses tumor genetics to predict treatment response
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.
COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.
Regeneron Science Talent Search top three finalists, Thomas Cong, Achyuta Rajaram and Michelle Wei.Achyuta Rajaram, a 17-year-old high school student from Exeter, NH, won $250,000 in a first-place award in the Regeneron Science Talent Search 2024.
Yosemite, an oncology-focused venture capital firm, and the American Cancer Society established the Yosemite-American Cancer Society Award with an initial commitment of $13.2 million.
